Drugs / pyrrotinib
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06235931 | Feb 2024 → Dec 2025 overdue | breast neoplasm | Second Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pyrrotinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06235931 ↗ |
| Action | Inhibit | “Pyrrotinib is a small molecule, irreversible, panerbb receptor tyrosine kinase inhibitor” NCT06235931 ↗ |
| Modality | Small molecule | “Pyrrotinib is a small molecule, irreversible, panerbb receptor tyrosine kinase inhibitor” NCT06235931 ↗ |